In cancer-associated VTE with high bleeding risk, what is the recommended anticoagulation?

• A. LMWH x 3 months
• B. DOACs x 3 months
• C. Warfarin x 6 months
• D. No anticoagulation

Answer: (A)

In cancer-associated VTE, the priority is to balance preventing recurrent clots with the patient’s bleeding risk in the context of ongoing cancer therapy. Low molecular weight heparin has consistently shown better protection against recurrent VTE in cancer patients compared with vitamin K antagonists, and it avoids many drug interactions and the need for frequent INR monitoring that complicate warfarin use during chemotherapy. While DOACs offer convenience and are effective in many settings, they can carry a higher risk of major bleeding in patients with cancer—especially for GI cancers—and their use can be complicated by drug interactions with cancer therapies. Warfarin is less favorable in this population due to unpredictable management and numerous interactions. Given a high bleeding risk, the safer, more effective choice is LMWH for a 3-month course, with the option to continue longer if the cancer remains active and bleeding risk is manageable.